Compare MDXH & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MDXH | ASRT |
|---|---|---|
| Founded | 2003 | 1995 |
| Country | Belgium | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.8M | 75.1M |
| IPO Year | 2021 | 1997 |
| Metric | MDXH | ASRT |
|---|---|---|
| Price | $3.36 | $9.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $7.67 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 112.3K | 30.2K |
| Earning Date | 11-12-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $103,069,000.00 | ★ $137,354,000.00 |
| Revenue This Year | $23.34 | N/A |
| Revenue Next Year | $22.98 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 21.68 | 9.22 |
| 52 Week Low | $1.35 | $7.71 |
| 52 Week High | $5.33 | $15.15 |
| Indicator | MDXH | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 43.35 | 93.32 |
| Support Level | $3.11 | $0.61 |
| Resistance Level | $3.58 | $10.42 |
| Average True Range (ATR) | 0.18 | 0.16 |
| MACD | 0.04 | 0.89 |
| Stochastic Oscillator | 52.79 | 90.42 |
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.